The first thing to remember is that everybody with a diagnosis of scleroderma is at risk of developing lung disease — either interstitial lung disease (ILD), which affects about 60 percent of patients, or pulmonary vascular disease, which can lead to pulmonary hypertension (PH) in as many as 10-15 percent of patients. The true prevalence of PH is likely even higher; the definition has been changed from 25mmg to 20mmHg on right heart catheterization (RHC).
In this edition of LEAP Rounds, Dr. Fredrick Wigley discusses the best protocol for early detection and treatment in Scleroderma Lung Disease.
Receive the Latest News from Johns Hopkins Rheumatology
Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.